A US policy perspective on oral preexposure prophylaxis for HIV.
Where this comes from
- Record sourced from PubMed, PMID 21493945.
- Also identified by DOI 10.2105/AJPH.2010.300066 and PMC identifier 3093264.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Orally administered preexposure prophylaxis is an innovative and controversial HIV prevention strategy involving the regular use of antiretroviral medications by uninfected individuals. Antiretroviral medications protect against potential HIV infection by reducing susceptibility to the virus. Recent clinical trial results indicate that preexposure prophylaxis can be safe and efficacious for men who have sexual intercourse with men, yet there remain policy considerations surrounding costs, opportunity costs, and ethical issues that must be addressed before broad implementation in the United States.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Health Policy
- Homosexuality, Male